Table 2.

Demographics, clinical and laboratory parameters in hemodialysis patients and kidney transplant recipients presented as responders versus non responders in each group after the second dose of vaccine.

	Hemodialysis patients (n = 34)		p	Kidney Transplant Recipients (n = 54)		p
	Responders (n= 31)	Non-Responders (n=3)		Responders (n=16)	Non-Responders (n=38)
Age, yr	69.2 ± 12	71.3 ± 17.6	0.78	55.01 ± 2.23	59.5 ± 7.48	0.18
Male sex	22, 71.0%	1, 33.3%	0.24	13, 81.3%	25, 65.8%	0.26
BMI, kg/m2	25.23 ± 4.19	23.77 ± 2.86	0.56	25.85 ± 3.99	25.98 ± 4.05	0.92
Diabetes mellitus	7, 22.6%	2, 66.7%	0.16	3, 18.7%	7, 18.4%	0.98
History of Cancer	1, 6.7%	–		1, 6.2%	4, 10.5%	0.62
Time on dialysis, years	5.81 ± 4.88	4.66 ± 1.53	0.69
Time from Transplant, years				12.94 ± 9.62	11.45 ± 7.70	0.55
Donor type
Deceased				9, 56.2%	26, 68.4%	0.55
Live				7, 43.8%	11, 28.9%
Both				–	1, 2.6%
ABO group			0.57			0.27
A	10, 32.2%	2, 66.7%		4, 25.0%	17, 47.2%
AB	2, 6.5%	–		–	2, 5.6%
B	8, 25.8%	1, 33.3%		2, 12.5%	5, 13.9%
O	11, 35.5%	–		10, 62.5%	12, 33.3%
Hb, g/dl	10.97 ± 1.00	9.37 ± 1.01	0.013	14.11 ± 1.85	13.30 ± 1.88	0.15
WBC, 103/ml	8326 ± 10050	6496 ± 4010	0.76	7961 ± 2751	8277 ± 2663	0.69
Tacrolimus				10, 62.5%	31, 81.6%	0.13
Cyclosporine				6, 37.5%	7, 18.4%	0.13
MMF/MPA				12, 75.0%	38, 100.0%	0.006
Steroids				12, 75.0%	34, 89.5%	0.17
Tacrolimus+MMF/MPA				8, 50.0%	31, 81.6%	0.018
Tacrolimus+MMF/MPA+Steroids				7, 43.8%	28, 73.7%	0.035
Tacrolimus levels, ng/ml				6.2 ± 1.7	6.8 ± 1.2	0.24
Cyclosporine T0 levels, ng/ml				102.6 ± 19.2	104.5 ± 26.0	0.88
eGFR, ml/min per 1.73m2				61.6 ± 15.4	48.9 ± 17.2	0.014
Urine Protein, mg/24h				307 ± 550	339 ± 345	0.80

BMI, body mass index; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid.